Provided by Tiger Fintech (Singapore) Pte. Ltd.

HCW Biologics Inc.

4.19
+0.13003.20%
Volume:29.60K
Turnover:122.35K
Market Cap:8.71M
PE:-0.14
High:4.20
Open:4.16
Low:4.03
Close:4.06
Loading ...

HCW Biologics Announces Pricing of $5.0 Million Follow-on Offering Priced at-the-Market Under Nasdaq Rules

THOMSON REUTERS
·
14 May

Nasdaq Rises Over 1%; Under Armour Posts Strong Q4 Sales

Benzinga
·
13 May

HCW Biologics Says Studies Show HCW9206 Fusion Protein Addresses Key Challenges for CAR-T Therapies; Shares Surge

MT Newswires Live
·
13 May

Hcw Biologics Inc trading halted, volatility trading pause

TIPRANKS
·
13 May

HCW Biologics Inc - Seeks Partnerships for HCW9206 Reagent Sale and/or Integration Into CAR-T Based Manufacturing Processes

THOMSON REUTERS
·
13 May

HCW Biologics Announces Positive Results of Studies of Proprietary Compound, HCW9206 and Availability for Commercialization

THOMSON REUTERS
·
13 May

HCW Biologics Inc. SVP Lee Flowers Reports Acquisition of Common Shares

Reuters
·
10 May

HCW Biologics Inc Files for Resale of up to $40 Mln of Shares of Common Stock - SEC Filing

THOMSON REUTERS
·
07 Apr

HCW Biologics to Implement 1-for-40 Reverse Stock Split

MT Newswires Live
·
02 Apr

HCW Biologics Announces Reverse Stock Split Approval

TIPRANKS
·
02 Apr

HCW Biologics approves 1-for-40 reverse stock split

TIPRANKS
·
02 Apr

BRIEF-HCW Biologics Announces 1-For-40 Reverse Stock Split

Reuters
·
02 Apr

HCW Biologics Announces 1-for-40 Reverse Stock Split

THOMSON REUTERS
·
02 Apr

HCW Biologics Announces 1-for-40 Reverse Stock Split

GlobeNewswire
·
02 Apr

HCW Biologics Q4 EPS $(0.08) Up From $(0.30) YoY, Sales $394.80K Down From $1.32M YoY

Benzinga
·
29 Mar

Press Release: HCW Biologics Reports Fourth Quarter and Fiscal Year 2024 Business Highlights and Financial Results

Dow Jones
·
29 Mar

HCW Biologics granted extension by Nasdaq to regain listing compliance

TIPRANKS
·
06 Mar

HCW Biologics Granted Extension by the Nasdaq Hearings Panel to Regain Compliance With Continued Listing Requirements

THOMSON REUTERS
·
06 Mar

HCW Biologics Granted Extension by the Nasdaq Hearings Panel to Regain Compliance with Continued Listing Requirements

GlobeNewswire
·
06 Mar

HCW Biologics: Buy Rating Affirmed Amid IND Clearance and Strategic Advancements

TIPRANKS
·
05 Feb